MorphoSys US, Inc.
MORNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MOR. That does not mean none is planned.
Get an email about MOR's next catalysts
Track MorphoSys US (MOR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Zanubrutinib
Mantle Cell Lymphoma
MOR202
Membranous Nephropathy
MOR103
Multiple Sclerosis
MOR00208
Contiguous Stage II Small Lymphocytic Lymphoma
MOR03087
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Zanubrutinib | Phase 2 | Mantle Cell Lymphoma | - | - |
MOR202 | Phase 2 | Membranous Nephropathy | - | - |
MOR103 | Phase 2 | Multiple Sclerosis | - | - |
MOR00208 | Phase 2 | Contiguous Stage II Small Lymphocytic Lymphoma | - | - |
MOR03087 | Phase 2 | Multiple Myeloma | - | - |
Frequently asked questions
What is in MorphoSys US, Inc.'s drug pipeline?β
CatalystAlert tracks 5 drug candidates in MorphoSys US, Inc.'s (MOR) pipeline across Phase 2. Its lead program is MOR00208 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MorphoSys US, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for MorphoSys US, Inc. (MOR) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track MOR biotech catalysts?β
Add MOR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MorphoSys US, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
